Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 109, Issue 29, Pages 11663-11668
Publisher
Proceedings of the National Academy of Sciences
Online
2012-07-03
DOI
10.1073/pnas.1205073109
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis
- (2011) Robert A. Copeland et al. ANALYTICAL BIOCHEMISTRY
- In VivoEfficacy of a Human-Simulated Regimen of Ceftaroline Combined with NXL104 against Extended-Spectrum-β-Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae
- (2011) Dora E. Wiskirchen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
- (2011) Jonathan Z. Long et al. CHEMICAL REVIEWS
- Current Trends in β-Lactam Based β-Lactamases Inhibitors
- (2011) S. Biondi et al. CURRENT MEDICINAL CHEMISTRY
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- Does broad-spectrum -lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?
- (2011) P. Nordmann et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Trapping Conformational States Along Ligand-Binding Dynamics of Peptide Deformylase: The Impact of Induced Fit on Enzyme Catalysis
- (2011) Sonia Fieulaine et al. PLOS BIOLOGY
- Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria
- (2010) Karen Bush et al. Annual Review of Microbiology
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae
- (2010) Andrea Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Drug–target residence time: critical information for lead optimization
- (2010) Hao Lu et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Current Challenges in Antimicrobial Chemotherapy
- (2010) Carine Bebrone et al. DRUGS
- The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety
- (2010) Robert A Copeland Expert Opinion on Drug Discovery
- Updated Functional Classification of -Lactamases
- (2009) K. Bush et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Three Decades of the Class A β-Lactamase Acyl-Enzyme
- (2009) Jed Fisher et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Antibiotic-Resistant Bugs in the 21st Century — A Clinical Super-Challenge
- (2009) Cesar A. Arias et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started